Development of effective cancer vaccines would help pre-MAGE-1 and -3 IgG antibody responses, respectively. Anivent and control tumor progression. A novel approach of mals immunized with plasmid alone did not induce antiimmunizing against tumor antigens is in vivo gene vacci-MAGE-1 or -3 IgG responses. Antibody responses could nation. We have developed a fusigenic viral liposome vecbe enhanced on reimmunization with the gene vaccines. tor using HVJ (hemagglutinating virus of Japan) and lipoMuscle biopsies taken after vaccine injection were verified some to deliver human tumor antigen genes effectively to to express gene-specific mRNA transcripts. Mice immuncells in vivo. Plasmids containing the human tumor antigen ized with MAGE-1 or -3 gene vaccines were shown to genes MAGE-1 and MAGE-3 were encapsulated in fusiinduce antibodies that could cross-react with the respective genic viral liposomes and injected into mice intramusculrecombinant proteins. This study demonstrates that in vivo arly. MAGE-1 and -3 recombinant proteins were used in immunization using HVJ-liposome containing human Western blotting and affinity ELISA for assessment of antitumor antigen genes can effectively deliver and induce body responses. Mice immunized with MAGE-1 and -3 immune responses to the respective whole proteins. gene vaccine individually were shown to produce anti-
Introduction assessed in immunizing cancer patients with tumor anti-DNA vaccines have recently been shown to be a promisgens. 5 Purification of natural or recombinant tumor antiing approach for immunization against a variety of infecgens is tedious and not always logistically practical. To tious diseases. [1] [2] [3] Delivery of naked DNAs containing date there are only a few human cancer vaccines showing microbial antigen genes can induce antigen-specific consistent and significant effective augmentation of immune responses in the host. The induction of antigenimmunity with soluble antigens (proteins/peptides). This specific immune responses using DNA-based vaccines problem is partially due to antigen presentation and host has shown some promising effects. 4 Overall the DNAmajor histocompatibility complex (MHC) polymorphism. based vaccination principle is similar to live attenuated Studies to date suggest that cellular cancer vaccines virus immunization however with a greater degree of expressing the antigens may be more effective than solcontrol of antigen expression, toxicity and pathogenicity, uble antigens alone. 5 This may be due to tumor antigen although improvements in in vivo delivery and transgene expression, processing and presentation by the cell. expression are needed. The majority of studies reported Using the host normal cells (nonhemopoietic) to express to date on DNA immunization are with microbial antigen and present the tumor antigens to the immune system genes that are known to be immunogenic in animals or may be an effective immunization strategy. In general, humans. DNA immunization strategy may be useful to when a cytopathic virus infects a host normal cell, the develop new effective cancer vaccines. In general, studies viral proteins are endogenously processed and presented on tumor antigen protein/peptide vaccines in human on the cell surface, or in fragments by MHC molecules. and animal studies to date have been encouraging but Foreign defined DNA transfected and expressed by nornot as efficient as microbial antigen vaccines. 5 Human mal cells can mimic viral infections. tumor antigens are in general weakly immunogenic. The
Although in vivo DNA vaccination protocols are availmethod of antigen presentation and the route of antigen able, there are still problems in effective in vivo delivery delivery are important to induce effective immunity as of DNA to the cells and expression of genes. One of the well.
problems is introduction of DNA into specific cells without degradation of the DNA by endosomes or lysosomes. 6 Current approaches of in vivo delivery of DNA proteins. To get around some of these problems, we have developed an in vivo delivery system using a nonviral DNA vector. The delivery system also includes protein encapsulated in a fusigenic viral liposome that is a hybrid vector of viral and nonviral reagents. Briefly, anionic liposomes are fused with HVJ (Sendai virus member of paramyxovirus family). [7] [8] [9] [10] HVJ proteins are known for their unique fusing properties to cell membranes of nonhemopoietic nucleated cells. 11, 12 This hybrid vector allows targeting to normal nonhemopoietic cells and delivery of encapsulated DNA into the cytoplasm of cells without lysosome/endosome degradation. Another advantage of the fusigenic viral liposome system is that it can deliver DNA and protein molecules together. Most gene transfer methods are limited to the low level of expression of the transfected gene. 8, 11 To facilitate gene transcription, we incorporated a high mobility group-1 protein (HMG) protein enhances gene transcription. This delivery system has been demonstrated to be highly effective in in vivo gene transfer and delivery of genes and antisense DNA amount of encapsulated plasmid DNA injected per animal was approximately 7-10 g. This dose was the most oligomers. 13, 14 Our objective was to utilize the HVJ-liposome DNAefficient amount of HVJ-liposome DNA complex needed for in vivo gene expression. This was also the most logismediated transfer technique in vivo to immunize against human tumor antigens MAGE-1 and MAGE-3. The tically feasible dose of vector to produce a significant rapid and consistent immune response to the MAGE pro-MAGE-1 and -3 antigens were first described in melanoma and subsequently demonstrated in various other teins. Optimization and control experiments with individual components of the fusigenic viral liposome for in cancers. MAGE-1 and -3 genes are expressed in Ͼ30% of melanomas and carcinomas such as lung, breast, liver vivo delivery of genes has been previously reported. 8, 9, 11 Immunization of mice immediately after HVJ-liposome and gastrointestinal cancers, [15] [16] [17] but not in normal tissues except testes. The MAGE-1 and -3 antigens were assessed preparation was performed to obtain optimal results. Through experimentation an optimal vaccine immunito study tumor antigen DNA vaccination primarily because they have been shown to be immunogenic, zation schedule was determined. No necrosis, inflammation or visible injury was expressed by a wide variety of human cancers and not expressed by normal tissues. [15] [16] [17] These are important criobserved after multiple injections at the same site. Groups of animals injected with plasmid DNA were kept teria in the overall design of an effective vaccine against multiple cancers. Studies have demonstrated that the for over 12 months and no visible injury or change in physical activity was observed compared with non-MAGE-1 and MAGE-3 proteins are immunogenic in which antigen-specific cell-mediated and humoral immunized animals. To assess the induction of anti-MAGE-1 and -3-specific antibody responses after vaccination recombinant human study we demonstrate that by immunization with HVJliposome containing MAGE-1 and -3 genes, anti-MAGE-MAGE-1 (rMAGE-1) and recombinant human MAGE-3 (rMAGE-3) were produced and purified for immuno-1 or -3 IgG antibodies could be induced. The antibody responses could be enhanced by reimmunization and assays ( Figure 2 ). MAGE-1 protein has 309 amino acids with a predicted molecular weight of 34 kDa. The purimaintained for several weeks.
fied rMAGE-1 run on SDS-PAGE under reducing conditions was approximately 42 kDa. MAGE-3 protein has
Results
314 amino acids with a predicted molecular weight of 35 kDa. The purified rMAGE-3 run on SDS-PAGE under reducing conditions was approximately 48 kDa. The Production of HVJ-liposomes A schematic diagram of the production of HVJ-lipopossible reasons for the differences in protein calibrated weight by gel electrophoresis versus predicted weight has somes encapsulated with plasmid pcDNA3 containing MAGE-1 (pMAGE-1) or MAGE-3 (pMAGE-3) and HMGbeen previously discussed. 16 Both proteins have additional amino acids used as affinity tags. Whole pro-1 protein is shown in Figure 1 . In the study we will refer to the HVJ-liposome complex containing pMAGE-1 and tein was essential to assess the overall immune response since antigenic peptide sequences in mice are not known. pMAGE-3 plus HMG-1 protein as MAGE-1 or -3 vaccine, respectively. Preparation of HVJ-liposomes with plasmid
Western blots with rMAGE-1 and rMAGE-3 were performed with sera of mice immunized at least twice to DNA was carried out on the day or within 24 h of injection into animals. The starting amount of plasmid DNA verify specificity of antibody responses ( Figure 2 ). No antibody (IgG) responses to rMAGE-1 or -3 were detected used in liposome encapsulation was 100 g per tube. The zations on day 14 IgG anti-MAGE-1 antibody titers were 1/200 to 1/400. A positive antibody dilution was considered when it was 2 s.d. above negative serum background at a dilution of 1:100. in non-immunized mice. Mice immunized several times with HVJ-liposome complex containing pcDNA3 withOne year after three immunizations antibody levels went back down to background level as expected. Aniout a MAGE-1 or -3 gene insert also had no antigenspecific antibody response. Naked DNA given in vivo mals were reimmunized and evaluated after 4 weeks. Anti-MAGE-1 IgG responses were shown to be boosted and taken up by cells degrades rapidly in lysosomes/endosomes (data not shown). Mice immunto early immunization levels. These studies indicated that repeated immunization with the HVJ-liposome system ized with MAGE-1 vaccine three times and assessed 6 weeks after immunization showed an induction of a does not induce any significant inhibiting immune response to the HVJ-liposome components or plasmid strong antibody response to rMAGE-1 ( Figure 2a ). Similarly mice immunized with MAGE-3 vaccine three times vector to prevent antigen-specific immunization. and followed-up after 6 weeks showed a strong antibody response to rMAGE-3 ( Figure 2b ). These studies indiCross-reactivity between MAGE-1 and MAGE-3 antibodies cated that antigen-specific IgG responses could be induced rapidly and maintained for at least 8 weeks after
Mice were immunized with MAGE-1 or -3 vaccine on days 0, 14 and 28. The objective of the study was to deterimmunization. IgM anti-MAGE-1 and -3 responses were also assessed after various numbers of immunization.
mine whether anti-MAGE-1 IgG antibodies induced by MAGE-1 vaccine immunization cross-reacted with The level of response was weak or non-detectable in sera tested; therefore we did not pursue further analysis of MAGE-3, and whether anti-MAGE-3 IgG antibodies induced by MAGE-3 vaccine immunization cross-reacted IgM responses.
with MAGE-1. Western blot analyses with rMAGE-1 and rMAGE-3 were performed with sera from MAGE-1 and Detection of anti-MAGE-1 and MAGE-3 IgG antibody by ELISA MAGE-3 vaccine immunized mice ( Figure 4 ). The studies demonstrated cross-reactivity of anti-MAGE-1 and Anti-MAGE-1 IgG antibodies were detected after immunization at various time-points by a MAGE-1 affin--MAGE-3 sera with both rMAGE-1 and rMAGE-3.
Further analysis of the cross-reactivity was shown by ity ELISA. The selective affinity binding of Ni 2+ and hexaHis tagged protein insured higher specificity and less ELISA ( Figure 5 ). There were no significant differences between the antibody responses against MAGE-1 (Figure steric conformation variation as opposed to conventional absorbance of proteins to ELISA plates. A representative 5a). However, anti-MAGE-3 IgG activity in MAGE-1 immunized mice was lower than that of MAGE-3 immuexperiment of antibody response after MAGE-1 immunization is shown in Figure 3 : mice were immunized on nized mice (Figure 5b ). Although both MAGE-1 and MAGE-3 have been shown to have distinct antigenic day 0, 7 and 14, and then reimmunized approximately 1 year after. IgG antibody levels were enhanced after 7 determinants in humans, and antigenic determinants have not been defined in the murine system. days of booster immunization and maintained at day 14. Detection of MAGE-1 DNA Muscle biopsies were analyzed for presence and expression of pcDNA3 and pMAGE-1 after selected periods of immunization. Tissue biopsies at the sites of vaccine injections were dissected out and nucleic acids were extracted. RT-PCR and DNA PCR plus Southern blots were performed on RNA and DNA, respectively, from muscle tissue of immunized mice and non-immunized mice ( Figure 6 ). Muscle biopsies of mice immunized with pcDNA3 alone were assessed 7, 14 and 28 days after immunization. Two mice from each time period were killed and assessed. A 218 bp RT-PCR and DNA PCR shown to express specific MAGE-1 mRNA 7, 14 and 28 days after immunization. MAGE-1 gene expression was further verified using a separate set of specific primers to MAGE-1 (RT-PCR cDNA product 920 bp). RT-PCR analysis of muscle biopsies at the site of MAGE-1 vaccine injection also showed the presence of the pcDNA3 plasmid alone (218 bp). This may be due to incomplete transcription of the MAGE-1 gene insert in pcDNA3 or contamination of pcDNA3 without MAGE-1 gene insert in vector preparations. This was observed in only a few animals injected with different HVJ-liposome. Normal muscle antibody responses to MAGE-1. Mice were immunized the host. Human cancer vaccines being studied today require culturing tumor cells, purifying tumor antigens, or producing specific peptide/recombinant proteins. The HVJ-liposome system avoids many of the tedious processes involved in vaccine preparation. Quality control and purity of plasmid DNA can be more easily monitored. Gene expression in muscle has been successful by injection of naked DNA of microbial antigens. 4 However, we found that HVJ-liposome-mediated gene transfer was 30-100 times more efficient in gene expression in skeletal muscle than naked DNA transfer (unpublished data). Fusigenic viral liposomes can provide an efficient vehicle to package, deliver and direct DNA to specific targets and at the same time protect against nucleic acid degrad- ing enzymes in body fluids and cytoplasmic organelles. 8 
Comparison of the anti-MAGE-1 IgG induction after immunization with
The delivery system using the HVJ-liposome is safe and normal cells is an effective attenuated form of human tumor antigen gene vaccination. In this type of situation (three times) with MAGE-1 DT vaccine as for MAGE-1 tumor antigen is expressed on a background of normal vaccine. The 16mer diphtheria toxin (DT) peptide cell(s) as opposed to a tumor cell. The latter has many sequence was tagged with a his-tag to allow peptide negative type regulating elements that may suppress affinity ELISA to be performed. The antibody response immune responses as well as altered physiologic functo rMAGE-1 assessed by Western blot after immunization tions which can modify antigen expression. Gene vacciwith MAGE-1 DT vaccine was not better than MAGE-1 nation provides an opportunity for molecular immunovaccine immunization (Figure 7 ). In assessment of mice physiologic manipulation of antigen expression that can immunized with MAGE-1 DT by affinity ELISA there be a useful tool in cancer vaccine design. Intramuscular was some enhancement (not significant) of antibody injection has been shown in the past to be an important response to DT peptide above control MAGE-1 vaccine delivery route for induction of immunity. Skeletal muscle (Figure 8) . Overall, adding a second immunogenic deterhas properties such as vascularization, multi-nucleation, minant did not improve antibody responses to rMAGE-1.
nonreplicating and capability of expressing recombinant proteins; 18 these offer advantages to intramuscular site injection for gene therapy. The mechanism of how muscle Discussion presents the protein and induces immune response is still In this study we have demonstrated a novel efficient unknown. One suggestion is that recombinant protein is approach using a fusigenic viral liposome system to produced and released into the vascular network of the deliver human tumor antigen genes in vivo to immunize muscle and eventually presented by professional antigenpresenting cells such as dendritic cells or macrophages infiltrating the muscle. 19 Another suggestion is that at the injection site muscle injury induces myoblast proliferation and activation of infiltrating macrophages/dendritic-like cells and they then present antigens through MHC class II antigens. 18, 19 Since IgG responses were detected the mechanism of antigen presentation is most likely through a T helper 2 subset response and MHC class II antigen presentation.
Analysis of muscle biopsies at the site of immunization showed that the plasmid DNA was being expressed after 28 days of immunization. The study verified that the expression of the plasmid DNA was transient and maintained in the cells at the site of injection for at least 1 month. This potentially provides a continual exposure of antigen to the host immune system as opposed to a single antigen injection. The advantage of the HVJ-liposome system over retroviral or adenoviral vectors is that it is not incorporated into the genome. The inactivated HVJ virus is safe and induces no pathogenic effect. The other advantage of the HVJ-liposome system is that it does not incorporate into hemopoietic-derived cells such as lym- immune responses towards the vector system to inhibit gene transfer. This is likely due to the rapid incorporation requires a polyvalent antigen vaccine to control human tumor progression effectively. 5 Recent studies have demof the fusigenic viral liposome into the host cells.
We and others have shown human cancer vaccines are onstrated the potential feasibility of immunization using a polynucleotide-mediated vaccine for carcinoembryonic an effective method of immunization of patients against tumor antigens to control tumor progression and antigen (CEA) and MUC-1. 26, 27 Further work on cancer gene vaccines will determine if such approaches are sigimprove survival. 5, 20, 21 Although there are many formulations of human cancer vaccines, there have been probnificantly effective in controlling tumor progression. lems in efficiently inducing specific antitumor antigen responses. Immunization protocols have not succeeded
Materials and methods
very well in consistently inducing anti-MAGE immune responses in humans. In this study we demonstrate con-MAGE-1 gene plasmid sistent induction of anti-MAGE-1 and -3 antibody MAGE-1 gene was cloned and isolated as previously responses shortly after vaccination and maintenance of described. 16 The MAGE-1 gene was cloned into the activity for several weeks. The antibody titers generated pcDNA3 plasmid vector designed for expression of prowere as expected for a weak immunogenic tumor antiteins in eukaryotic cells (InVitrogen, San Diego, CA, gen. There is a possibility that T cell responses were USA). The pcDNA3 has an enhancer-promotor sequence induced, however, at this time we do not know the antifrom the immediate-early gene of the human cytomegagenic determinants of the antigens in mice to allow lovirus, and a polyadenylation signal and transcription assessment. Future studies will examine the induction of termination sequence from the bovine growth hormone MAGE-1 and/or -3-specific T cells. To date, anti-MAGEgene. The MAGE-1 gene insert in pcDNA3 was verified 1 and -3 T cell responses in mice have not been docuby DNA sequencing. The pcDNA3 containing MAGE-1 mented. Two highly homologous sequences of MAGE-1, gene (pMAGE-1) was purified by equilibrium ultracentrireferred to as Smage1 and Smage2 are expressed in the fugation using CsCl-ethidium bromide gradient. Purified murine testes but not normal murine tissue. 22 There may plasmid DNA was dissolved in 10 mm Tris-HCl, pH 8.0, be host immune tolerance to the MAGE family proteins.
0.1 mm EDTA, assessed by spectrophotometry and Studies reported on generation of anti-MAGE-1 and -3 in shown to have an A260/A280 ratio of 1.9 or higher. mice by recombinant protein administration with adjuFurther analysis by gel electrophoresis was carried out to vants have in general not produced high antibody titers. 23 verify the purity of the purified plasmid. We assessed the incorporation of an immunogenic determinant DT as a 'helper' antigen on the MAGE-1
Expression and purification of rMAGE-1 gene to improve its efficacy. Diphtheria toxin B fragment rMAGE-1 was expressed as previously described and COOH-terminal region has been shown to be immunopurified by an affinity column containing Ni
2+
-NTA resin genic in mice. 24 The failure to enhance anti-MAGE-1 (Qiagen, Chatsworth, CA, USA). 16 The rMAGE-1 conresponses could be due to the lack of full expression of struct was tagged at the amino terminal end with the MAGE-1 DT hybrid protein in vivo, conformation of the sequence Gly-Ser-hexaHis for affinity purification and recombinant MAGE-1 DT protein, or lack of recognition affinity ELISA. The recombinant protein was further of DT peptide by the host as an immunogenic determipurified by gel electrolution and a Biologic FPLC system nant due to presentation. A low level of response was (Bio-Rad, Richmond, CA, USA) for analysis. Recombiobserved against DT peptide alone suggesting some nant proteins were run in Laemmli 10% SDS-PAGE gel induction of immune response. Alternatively, a T cell under reducing conditions. response may have been induced. Further work needs to be carried out in the development of chimeric gene MAGE-3 gene plasmid constructs for gene vaccination to improve immunocDNA (942 bp) encoding full-length MAGE-3 was ampligenicity and polyvalency.
fied by PCR from a human testis library (Clontech, Palo Both MAGE-1 and MAGE-3 have been shown to be Alto, CA, USA). The PCR cDNA product obtained was immunogenic in humans. There are other MAGE gene digested with restriction enzyme and the appropriate size family members with similar homologies. 25 The strategy fragment was subcloned into the vector pET30b of using two dominant immunogenic MAGE family anti-(Novagen, Madison, WI, USA) with hexaHis on the Cgens may be beneficial in that they can elicit immunity terminus, resulting in a plasmid designated pSH007. The to a wide spectrum of MAGE antigens expressed by diffull length MAGE-3 cDNA was sequenced by dideoxynuferent human tumors. The cross-reactivity of the anticleotide sequencing method using T7 DNA polymerase MAGE-1 and MAGE-3 responses demonstrated is not (USB, Cleveland, OH, USA). Plasmid pSH007 was surprising since the proteins express 66% amino acids digested by EcoRV and NotI and the EcoRV-NotI fragment homology. 17 Cross-reactivity to MAGE-1 and MAGE-3 containing MAGE-3 gene was then inserted into the has not been previously well documented. The availpcDNA3 plasmid. The pcDNA3 containing MAGE-3 ability of the recombinant MAGE proteins and immungene (pMAGE-3) was purified and prepared as ized mice sera has allowed us to assess these events. The pMAGE-1. study also indicated that vaccination with MAGE-1 or -3 could potentially induce immune responses to tumors expressing either antigen. MAGE-1 and MAGE-3 are not A DNA Expression and purification of rMAGE-3 DNA fragment of MAGE-3 gene with the terminal hexaalways coexpressed in the same tumor biopsy or cell lines.
His affinity tag was removed from pSH007 and inserted into the SmaI site of pGEX-2T (Promega, Madison, WI, Multiple genes can be incorporated into our delivery system to produce a polyvalent DNA cancer vaccine. It USA). This expression plasmid was transformed into E. coli strain BL21 cells. Recombinant fusion protein was is becoming clearer now that effective tumor vaccination induced by isopropyl-d-thiogalactoside (IPTG) and puridetermined by spectrophotometry. Preparation of liposomes involved mixing bovine brain l-␣-phosphatidylfied from bacterial lysates by affinity chromatography using Glutathione Sepharose 4B (Pharmacia, Piscataway, serine sodium salt (Avanti Polar-lipids, Alabaster, AL, USA), egg yolk l-␣-phosphatidylcholine (Sigma, St Louis, NJ, USA). Before the elution of fusion protein, rMAGE-3 was cleaved from the GST carrier by adding thrombin to MO, USA), and cholesterol (Sigma) in a glass tube at a weight ratio of 1:4, 8:2 with tetrahydrofuran (Nakarai, the bound fusion protein and eluted off. The FPLC purified rMAGE-3 was verified by SDS-PAGE gel and WestKyoto, Japan). The tube of lipid mixture was evaporated using a rotary evaporator while under 400 mm vacuum ern blotting using Ni 2+ -NTA conjugate (Qiagen), and then used for ELISA and Western blotting.
pressure and immersed in a 45°C water bath. HMG-1 protein was purified from calf thymus as previously described. 11 Purified plasmid DNA (200 g) was mixed MAGE-1 DT gene plasmid The complementary oligonucleotide sequences (sense: 5′ with HMG-1 (65 g) and BSS (137 mm NaCl, 5.4 mm KCl, 10 mm Tris-HCl, pH 7.6) in nuclease-free tubes. The mix-AGCTTACGCAACCATTTCTTCATGACGGGTATGCTG TCAGTTGGAACACTGTT G-3′; antisense: 5′TCGACAA ture was incubated in a water bath at 20°C for 1 h. The HMG-1:DNA mixture was then added to the lipid mix-CAGTGTTCCAACTGACAGCATACCCGTCATGAAG A AATGGTTGCGTA-3′), derived from diphtheria toxin ture and agitated intensely by vortexing, water bath sonication and incubation in a 37°C water bath for eight fragment B nucleotide sequence, corresponding to the Cterminal end 16 amino acid residue TQPFLHDGY cycles. Balanced salt solution (BSS) was added to the unilamellar liposomes:HMG-1:DNA, incubated in a 37°C AVSWNTV were synthesized. The sequences were hybridized and inserted into the HindIII-SalI sites of water bath (shaking) and then put in an ice bath. Purified HVJ was inactivated with UV irradiation 10 J/m 2 /s for pBluescript. cDNA encoding full length of MAGE-1 was then inserted into BamHI-EcoRV sites, fusing it to the N-3 min. Inactivated HVJ (30 000 HAU) was added to the DNA:liposome solution, incubated on ice for 10 min and terminus of the DT peptide nucleotide sequence. The cDNA clone was sequenced by the dideoxynucleotide then incubated in a 37°C shaking water bath for 1 h. Free HVJ was then removed from HVJ-liposomes by sucrose sequencing method using T7 DNA polymerase (USB). The BamHI-XhoI fragment containing MAGE-1 DT gene density gradient centrifugation. HVJ-liposomes were then carefully removed from the density gradient, was then inserted into the pcDNA3 plasmid. The plasmid MAGE-1 DT was purified as described for pMAGE-1.
washed, precipitated by centrifugation (27 000 g, 30 min), resuspended in sterile BSS plus 2 mm CaCl 2 and kept on ice until used. PCR and Southern blot analysis RT-PCR and DNA PCR plus Southern blot analyses of MAGE-1 were performed as previously described. 28 PCR cDNA products of MAGE-1 were evaluated by gel Immunization protocol The HVJ was treated with detergent, heat and UV light electrophoresis on a 2% agarose gel and visualized by ethidium bromide staining under UV light. Southern blot inactivating any pathogenic effects in the host. C57BL/6 male mice 6 to 8-weeks old in groups of three or four analysis of gel electrophoresed PCR cDNA product was performed using a MAGE-1-specific cDNA probe. The were used in each experiment. Mice were lightly anesthetized with ether vapor and injected (150 l) with HVJpcDNA3, pMAGE-1 and MAGE-1 gene insert alone PCR cDNA products were 218 bp, 1136 bp and 920 bp, liposome solution in the right quadricep hind leg muscle only with a sterile 26-gauge needle syringe. Animals respectively. The sequences of the primers were as follows: pcDNA3; 5′ primer was 5′-TAATACGACTCACTAwere bled before vaccination and at designated timepoints. Before bleeding animals were anesthetized using TAGGG-3′ and the 3′ primer was 5′-AGGGGCAAACAA-CAGATGGC-3′ that gave a 218 bp cDNA product for ether vapor and subsequently retro-orbital bled using sterile glass polished Pasteur pipettes. Blood (approxipcDNA3 alone and a 1136 bp cDNA product for pcDNA3 with MAGE-1 insert. mately 250 l) was collected in 0.5 ml Eppendorf tubes, clotted at 4°C and centrifuged at 700 g for 5 min. The Mouse tissue was obtained from animals killed at designated time-points after vaccinations. The hind serum was carefully removed and aliquoted into Eppendorf tubes and stored at −30°C until used. muscle at the site of injection was aseptically dissected, minced into small pieces and processed for RNA and DNA. Total RNA and DNA from the tissue biopsies was extracted, isolated and purified using Tri-Reagent Western blotting Affinity purified recombinant proteins (5 g) were pre-(Molecular Research Center, Cincinnati, OH, USA) protocol according to the manufacturer's instructions. RNA pared and Western blotting was carried out as previously described. 16 The blots were blocked with SuperBlock and DNA extraction was carried out in a designated sterile laminar flow hood with RNase and DNase-free labblocking buffer (Pierce, Rockford, IL, USA) overnight at room temperature. Blots were tested with various mouse ware. Purified RNA and DNA was quantified and assessed for purity by UV spectrophotometry. Normal serum dilutions in PBS. After washing several times blots were incubated with alkaline phosphatase-conjugated muscle and other body organs were assessed from nonimmunized animals of the same sex and age group. goat anti-mouse IgG (␥-chain specific) or IgM (-chain specific) (Caltag, San Francisco, CA, USA). Blots were washed and developed using 5-bromo-4-chloro-3-indoPreparation of HVJ-liposomes HVJ-liposomes were prepared as previously described. 11 lyl-1-phosphate and Nitro blue tetrazolium (Promega). Negative controls were conjugate alone with developing Briefly, HVJ (Z strain) was prepared from chorioallantoic fluid of virus inoculated embryonated chick eggs and the solution, non-immunized mice sera (age and sex matched), and pcDNA3 alone immunized mice. hemagglutinating units (HAU) of the virus titer was
